Log in
NYSEARCA:FFTY

Innovator IBD 50 ETF Stock Forecast, Price & News

$38.33
+0.30 (+0.79 %)
(As of 10/23/2020 12:00 AM ET)
Add
Today's Range
$37.99
Now: $38.33
$38.33
50-Day Range
$35.66
MA: $37.47
$39.94
52-Week Range
$24.03
Now: $38.33
$40.12
Volume20,090 shs
Average Volume100,387 shs
Market Capitalization$197.40 million
P/E RatioN/A
Dividend Yield0.00%
BetaN/A

Geographic Exposure of FFTY

Currency Exposure of FFTY

Sector Exposure of FFTY

Industry Exposure of FFTY

Basic Details

Issuer Innovator Capital Management
Fund NameInnovator IBD 50 ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:FFTY
Inception Date4/8/2015
Fund ManagerDustin Lewellyn, Ernesto Tong, Anand Desai
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkIBD 50 Index
CategoryBroad Equity
FocusBroad Equity
Development LevelBlended Development
RegionGlobal

Fund Statistics

Assets Under Management$199.72 million
Average Daily Volume$79,820.80
Discount/Premium-0.04%

ETF Expenses

Management Fee0.70%
Other Expenses0.33%
Total Expenses1.03%
Fee Waiver-0.23%
Net Expenses0.80%

Administrator, Advisor and Custodian

AdministratorU.S. Bancorp Fund Services, LLC
AdvisorInnovator Capital Management, LLC
CustodianU.S. Bank, N.A.
DistributorForeside Fund Services, LLC
Transfer AgentU.S. Bank, N.A.
Trustee
Lead Market MakerVirtu Financial
$38.33
+0.30 (+0.79 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FFTY News and Ratings via Email

Sign-up to receive the latest news and ratings for FFTY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Innovator IBD 50 ETF (NYSEARCA:FFTY) Frequently Asked Questions

How has Innovator IBD 50 ETF's stock price been impacted by COVID-19 (Coronavirus)?

Innovator IBD 50 ETF's stock was trading at $29.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FFTY stock has increased by 29.5% and is now trading at $38.33.
View which stocks have been most impacted by COVID-19
.

What other stocks do shareholders of Innovator IBD 50 ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovator IBD 50 ETF investors own include NVIDIA (NVDA), Alibaba Group (BABA), Bank of America (BAC), AbbVie (ABBV), Advanced Micro Devices (AMD), Arista Networks (ANET), Activision Blizzard (ATVI), Micron Technology (MU), Adobe (ADBE) and Applied Materials (AMAT).

What is Innovator IBD 50 ETF's stock symbol?

Innovator IBD 50 ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "FFTY."

Who are Innovator IBD 50 ETF's major shareholders?

Innovator IBD 50 ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.29%), Cliftonlarsonallen Wealth Advisors LLC (0.21%), Avantax Advisory Services Inc. (0.11%) and Toth Financial Advisory Corp (0.04%).

Which major investors are selling Innovator IBD 50 ETF stock?

FFTY stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc..

Which major investors are buying Innovator IBD 50 ETF stock?

FFTY stock was acquired by a variety of institutional investors in the last quarter, including Cliftonlarsonallen Wealth Advisors LLC, Avantax Advisory Services Inc., and Toth Financial Advisory Corp.

How do I buy shares of Innovator IBD 50 ETF?

Shares of FFTY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innovator IBD 50 ETF's stock price today?

One share of FFTY stock can currently be purchased for approximately $38.33.

How big of a company is Innovator IBD 50 ETF?

Innovator IBD 50 ETF has a market capitalization of $197.40 million.

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.